Diabetes + Obesity: Unraveling the Role of Incretins

PRETest
https://surveys.dwahcg.com/snapwebhost/s.asp?k=165521705970

POSTTest and Evaluation
https://surveys.dwahcg.com/snapwebhost/s.asp?k=165515861227

Planned by: Forefront Collaborative, Inc.
Provided by an education grant from: Eli Lilly and Company

Diabetes and obesity often go hand in hand. Nearly 90% of those with type 2 diabetes mellitus (T2D) also have an overweight or obesity diagnosis. For clinicians, managing both can be a challenge. Join us as we take a fresh look at treating these conditions together in this 90-minute presentation.

As part of this interactive activity, we’ll unravel the role of incretins in T2D and weight reduction through a “MythBusters” session. We’ll also provide a scientific update on glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide 1 (GLP-1) receptor agonism. Come prepared to share your opinion on the treatment of T2D in a patient case discussion. Finally, receive tips for addressing weight reduction with your patients through shared decision making.

Learning Objectives:
As a result of participation in this activity, participants will increase their ability to:
• Identify appropriate people with T2D, early, who may benefit from treatment intensification
• Describe safety and efficacy data for the treatment of people with obesity and T2D
• Explain the role of incretins, GIP and GLP-1, in T2D and benefits of dual agonism to glycemic control and other health-related factors
• Facilitate people with T2D in developing effective strategies to achieve effective weight reduction, including use of shared decision making

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.
*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.